International Edition
Latest News
Health

GLP-1 Drugs Could Free Farmland Larger Than Italy, Prevent 6.6M Deaths by 2050

"Our findings suggest that these changes in food consumption could have consequences that extend beyond the individuals receiving treatment," said Dr Roslyn Henry, lead author of the study published in Nature Communications. Widespread use of GLP-1 medications such…

GLP-1 Drugs Could Free Farmland Larger Than Italy, Prevent 6.6M Deaths by 2050

“Our findings suggest that these changes in food consumption could have consequences that extend beyond the individuals receiving treatment,” said Dr Roslyn Henry, lead author of the study published in Nature Communications.

Widespread use of GLP-1 medications such as Ozempic and Mounjaro for obesity could prevent up to 6.6 million deaths globally in 2050 and free 32 million hectares of agricultural land, an area slightly larger than Italy, according to a global food-system model developed by researchers at the University of Aberdeen, the University of Edinburgh and Scotland’s Rural College (SRUC).

Combining the drugs with a shift toward the EAT–Lancet diet raises the projected benefits to 7.7 million avoided deaths and 46 million hectares of land returned to nature, the study found.

The model shows that reduced demand from medication users could lower food prices, which in turn may increase consumption among untreated populations — including of unhealthy foods — partially offsetting the mortality and land-use benefits, NewsCord reported.

GLP-1 Drugs Could Free Farmland Larger Than Italy, Prevent 6.6M Deaths by 2050
Photo: theconversation.com

“What we eat has consequences that extend beyond our own health,” said Professor Peter Alexander of the University of Edinburgh, a co-author. He tied those consequences to what farmers produce, what countries trade and how much land agriculture requires.

Global obesity prevalence has nearly tripled since 1975, the study notes. The World Health Organization issued its first recommendation supporting GLP-1 therapies for obesity treatment in December 2025, but the drugs remain inaccessible in many countries.

Uptake has risen in high-income nations: approximately 12% of U.S. adults reported using the medications as of November 2025, compared with about 2.9% of U.K. adults in 2025, according to figures cited in the Nature Communications paper.

The study authors reported that about 100 million people worldwide already use GLP-1 weight-loss medications.

The research team stressed that the findings should not be read as placing environmental responsibility on people living with obesity. “Improving diets can’t simply be about asking individuals to choose better,” the UK government’s National Food Strategy concluded in 2021, a point the authors echoed in The Conversation.

Rather than asking whether GLP-1 medications or healthier diets are the answer, the authors argue for a food system where healthier foods are affordable and accessible, unhealthy options are not relentlessly promoted, agricultural policy supports nutritious and sustainable production, and people who need medical treatment can access it.

Study: Nature Communications

About the author: Health Desk

Health Desk at Archynewsy.